GAO: HHS Illegally Withheld $78M in Health Funds

The U.S. Government Accountability Office (GAO) determined on October 7, 2026, that the Department of Health and Human Services (HHS) unlawfully withheld $78 million in funds intended for the Agency for Healthcare Research and Quality (AHRQ). This finding stems from a GAO review initiated after AHRQ officials expressed concerns about the withholding of these funds, which were appropriated by Congress for fiscal year 2023. The GAO's decision, detailed in a report, concluded that HHS did not have a legal basis to impound the funds, which were earmarked for specific research and improvement initiatives within the healthcare sector. The withheld funds represent a significant portion of AHRQ's budget and were intended to support its mission of producing evidence to make healthcare safer, higher quality, more accessible, equitable, and affordable. AHRQ is a primary federal entity for research on healthcare quality, safety, and effectiveness. Its work informs policy and practice changes aimed at improving the health of all Americans. The agency's research agenda typically covers a broad range of topics, including health services research, comparative effectiveness research, and patient safety initiatives. The GAO's legal opinion is binding on federal agencies, meaning HHS is expected to release the funds to AHRQ. The report did not specify a timeline for the release of the funds but indicated that the agency's continued withholding was contrary to law. This situation highlights potential inter-agency disputes over budgetary control and the allocation of congressionally appropriated funds. The GAO acts as a legislative branch agency that provides auditing, evaluation, and investigative services for the United States Congress. Its role is to support Congress in meeting its oversight responsibilities. The agency's findings are often critical in shaping policy and ensuring accountability within federal departments. The specific appropriation in question was part of the broader federal budget process, where Congress allocates funds to various agencies for specific purposes. The dispute arose over the interpretation of the appropriation language and the executive branch's authority to withhold funds under certain circumstances. The GAO's review focused on whether HHS followed proper legal procedures and provided sufficient justification for its decision to withhold the $78 million. The agency's conclusion that HHS acted unlawfully suggests a failure to meet these legal standards. The implications of this ruling extend beyond the immediate financial impact on AHRQ, potentially setting a precedent for how congressionally appropriated funds can be managed and challenged within the federal government. The withheld funds were intended to support critical research aimed at improving patient outcomes and reducing healthcare costs, areas that have been central to national health policy discussions. The delay in accessing these funds could impact the progress of ongoing research projects and the initiation of new evidence-generation efforts. The GAO's report is a public document, and its findings are likely to be scrutinized by lawmakers and healthcare stakeholders. The resolution of this matter will involve HHS complying with the GAO's determination and releasing the funds to AHRQ, thereby restoring the agency's full budgetary capacity for the fiscal year 2023 appropriations. The agency's ability to conduct timely and impactful research is directly tied to its financial resources, making the recovery of these funds a priority for its operations and its contribution to national health improvement goals.